Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.33 |
| ▸ | SPR | P35270 | 3/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352529 | 0.92 | NTRK1 (0.36) | NTRK1NTRK3NTRK2SPRPDE10A | |
| SCHEMBL16947091 | 0.88 | TSHR (0.39) | NTRK1L3MBTL1 | |
| SCHEMBL29511257 | 0.88 | TSHR (0.39) | NTRK1L3MBTL1 | |
| SCHEMBL16947095 | 0.85 | NTRK1 (0.38) | NTRK1NTRK3NTRK2SPRPOLB | |
| SCHEMBL16946723 | 0.82 | NTRK1 (0.50) | NTRK1NTRK3NTRK2 | |
| SCHEMBL18352547 | 0.77 | NTRK1 (0.51) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21229436 | 0.75 | SMPD3 (0.55) | NTRK1NTRK3NTRK2 | |
| SCHEMBL19614122 | 0.74 | NTRK1 (0.49) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16935988 | 0.73 | NTRK1 (0.49) | NTRK1NTRK3NTRK2 | |
| SCHEMBL29511265 | 0.73 | NTRK1 (0.49) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3636650-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3097107-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-3097107-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP Therapeutics, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.